Compare Baxter International Inc (BAX) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs MobilEye Global Inc — how do they compare? Baxter International Inc trades at $21.87 (market cap $11.26B), while MobilEye Global Inc trades at $10.15 (market cap $8.50B). The key difference: Baxter International Inc is the larger of the two by market cap, and Baxter International Inc pays a 0.92% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| BAX | MBLY | |
|---|---|---|
Market Cap | $11.26B | $8.50B |
Sector | Health | Technology |
52-Week High | $29.22 | $16.27 |
52-Week Low | $15.80 | $6.56 |
Enterprise Value | $18.93B | $7.15B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
MBLY trades at $9.75, up 2.09% today, with a bullish technical signal and strong analyst support (57.69% buy ratings). The company reported Q1 2026 EPS of $0.12, beating expectations, but faces profitability challenges with a net income margin of -203.97% for 2026. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it beyond traditional ADAS supply.
The outlook hinges on MBLY's execution of its robotaxi initiative, offering growth potential but carrying significant execution and competitive risks. While near-term fundamentals show losses, the stock's current price near the consensus target of $10.50 suggests limited upside unless profitability improves or new ventures accelerate. Investors should weigh the high-risk, high-reward profile amid volatile earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
